findmyKOL
Clinical trialNCT03459846Active, not recruitingPhase 2Interventional

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

SponsorAstraZenecaEnrollment154Urinary Bladder Neoplasms
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

44 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Research Site

    Greater Sudbury, Ontario, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    Newmarket, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

Russia
  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

South Korea
  • Research Site

    Incheon, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Spain
  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Málaga, Spain

  • Research Site

    Santiago de Compostela, Spain

Taiwan
  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Kaohsiung City, Taiwan

  • Research Site

    Taichung, Taiwan

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan City, Taiwan

United States
  • Research Site

    Birmingham, Alabama, United States

  • Research Site

    Goodyear, Arizona, United States

  • Research Site

    Fort Myers, Florida, United States

  • Research Site

    St. Petersburg, Florida, United States

  • Research Site

    Tampa, Florida, United States

  • Research Site

    Louisville, Kentucky, United States

  • Research Site

    New Hyde Park, New York, United States

  • Research Site

    New York, New York, United States

  • Research Site

    The Bronx, New York, United States

  • Research Site

    Philadelphia, Pennsylvania, United States

4 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Durvalumab →Olaparib →Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Mar 2018
Primary completion
15 Oct 2020
Completion
31 Dec 2026
Last update posted
5 Aug 2026
Registered enrollment
154
Registry id
NCT03459846

Cross-registrations

EU-CTR / CTIS (EudraCT)2017-004556-27
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.